A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution

J Drugs Dermatol. 2005 Jan-Feb;4(1):64-70.

Abstract

Background: Blue light sources have been shown to be effective in the treatment of mild to moderate inflammatory acne vulgaris lesions.

Objective: We evaluated the safety and efficacy of a new blue light source in the treatment of mild to moderate inflammatory acne vulgaris in comparison to topical 1% clindamycin solution.

Results: Blue light therapy reduced inflammatory acne vulgaris lesions by an average of 34%, as compared to 14% for topical 1% clindamycin solution.

Conclusions: The blue light source presented in this report is a safe and effective treatment option available to our patients with mild to moderate inflammatory acne lesions.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Acne Vulgaris / drug therapy*
  • Acne Vulgaris / therapy*
  • Administration, Topical
  • Adolescent
  • Adult
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use*
  • Clindamycin / administration & dosage
  • Clindamycin / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pharmaceutical Solutions
  • Photochemotherapy*
  • Pilot Projects

Substances

  • Anti-Bacterial Agents
  • Pharmaceutical Solutions
  • Clindamycin